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ABSTRACT 
This thesis deals with the Adrenergic Beta Receptor Blocking 
drugs. It covers some aspects of general pharmacology that must be 
considered when prescribing beta blocker drugs. The eleven beta 
blockers that have currently met FDA approval are then detailed 
with respect to their specific clinical applications, pharmacology, side 
effects, contraindications, and advantages and disadvantages. 
The Adrenergic Beta Receptor Blocking drugs, more commonly 
referred to as the beta-blockers, are a class of drugs that are 
expanding at a phenomenal rate. The amount of research on beta 
blockers has been large yet they are still not well understood. Their 
two main areas of use are in heart therapy for managing 
hypertension, angina, and arrhythmias and in the management of 
open angle glaucoma by lowering intraocular pressure in the eye. 
This paper will deal with the pharmacology, clinical applications, side 
effects, contraindications, and the advantages and disadvantages of 
the most common beta blockers. A section on some of the general 
pharmacological aspects of the beta blockers will be covered first and 
then the eleven most commonly used beta blockers that have met 
Federal Drug Administration(FDA) approval, Timolol, Betaxolol, 
Levobunolol, Metipranolol, Propranolol, Nadolol, Acebutolol, Atenolol, 
Pindolol, Labetalol, and Metoprolol will be covered in detail. The 
numerous other beta blockers that are currently being researched 
but have not achieved FDA approval will not be included in this 
paper. 
Many factors must be considered when a beta blocker is being 
considered for systemic or ocular therapy. The more important ones 
that will be covered are beta receptor selectivity, lipophilicity, 
systemic effects with ocular administration, long-term drift, intrinsic 
sympathomimetic activity, hepatic affect, active metabolites, first-
pass metabolism, protein binding, and renal affects. Of these beta 
receptor selectivity will be covered first. 
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The beta receptors are part of the larger Autonomic Nervous 
System that regulates the activities of smooth muscle, cardiac muscle, 
and glands. The Autonomic System is divided into two large 
divisions, the sympathetic and the parasympathetic. Most organs 
and muscles receive input from both of these systems with one 
division stimulating the muscle or organ and the other division 
inhibiting it. There are two main classes of adrenergic receptors m 
the Autonomic System, alpha and beta. The alpha receptors are 
usually excitatory causing smooth muscle contraction, peripheral 
vasoconstriction, increased cardiac output and exocrine gland 
secretion, and pupillary dilation from dilator muscle contraction. The 
beta receptors are subdivided into two classes, beta1 and beta2 
receptors. This division is based on the relative concentrations of the 
receptors in different parts of the body. The betat receptors are 
found mainly in the heart while the beta2 receptors are located in 
the lungs, the ciliary body in the eye, the liver, the pancreas, and in 
peripheral blood vessels. The beta1 receptors in the heart are 
excitatory causing an increased heart rate. The beta2 receptors in 
the lungs induce bronchiodilation, in the ciliary body they stimulate 
aqueous humor production, in the liver they stimulate glycogenolysis 
which results in glucose release, in the pancreas they stimulate 
insulin release, and in the peripheral blood vessels they stimulate 
v asodil a ton. 
Each beta blocker exhibits a certain receptor selectivity from 
non-selective, which blocks both betat and beta 2. to only blocking 
one or the other type of beta receptor. The particular selectivity of a 
specific drug then should theoretically affect one receptor group 
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more than the other. A betaz blocker should inhibit dilation of the 
bronchioles and decrease aqueous humor production. In reality 
though, it only follows theory partially. It is known that if enough 
beta 1 blocker is present that it will also block betaz receptors and 
visa versa. Theory has enough validity though to warrant 
consideration when prescribing a beta blocker. This can be shown 
with Betaxolol, a beta1 cardio-selective blocker, which has been 
shown to cause fewer problems in patients with bronchiole asthma.1 6 
(Refer to Appendix 1 for the beta receptor selectivity of the different 
beta blockers). 
Even with topical administration of a beta blocker on the eye 
there are systemic side effects that can occur.1 This happens when 
the beta blocker is absorbed directly into the blood stream in the 
conjunctivial and nasal mucosal capillaries as the drop leaves the eye 
through the lacrimal drainage system. This systemic absorption can 
be significantly decreased though by simply occluding the nasal-
lacrimal drainage system with digital pressure or by closing the 
eyelids for five minutes.32 Without either of these measures being 
applied with ocular administration, systemic side effects such as 
dyspnea, bradycardia, decreased cardiac output, increased peripheral 
vascular resistance, and CNS penetration resulting in depression, 
hallucinations, and confusion can occur. 
Long-term drift is a consideration when using topical beta 
blockers to lower lOP in the eye. This occurs slowly over the first 
several years as the lOP will sometimes drift back up agam even 
with continued beta blockade. Therefore it should not be assumed 
that the lOP will stay under control if control is achieved initially. A 
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patient's lOP should be checked every month for the first three 
months and then every three months thereafter to assure that long-
term drift does not occur. 
Another consideration m prescribing a beta blocker is Intrinsic 
Sympathomimetic Activity. By definition, beta blockers are 
antagonistic to the beta adrenergic receptors which makes them 
sympatholytic drugs; they decrease the sympathetic tone within the 
body. Some of the beta blockers, Pindolol, Labetalolol, and 
Acebutolol, have also shown a certain degree of agonistic ability 
which has been termed Intrinsic Sympathomimetic Activity or ISA. 
If ISA is present it will decrease the magnitude of beta blockage by 
also slightly increasing the amount of agonistic activity. 
Interestingly, if the intrinsic sympathomimetic activity is beta2 type 
it should, in theory, actually cause slight bronchiole dilation. The ISA 
effect is actually dependent on the overall sympathetic tone of the 
body though. During exercise, when sympathetic tone is strong, 
there is no ISA effect but when tone is low, like when a person 1s 
sleeping, a beta blocker with beta2 type ISA actually showed a slight 
increase in heart rate. 27 A beta blocker with ISA also causes less 
beta blockade hypersensitivity. In prolonged systemic beta blockade 
a hypersensitivity to catecholamines can develop so that if they are 
abruptly withdrawn, it can cause a large rush of sympathetic input 
that can actually lead to heart failure. Therefore a beta blocker with 
ISA does not need to be withdrawn as carefully as one without it. 
This could be critical in an emergency. There is also evidence that 
ISA beta blockers have less of a disturbance in certain metabolic 
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processes such as lipid metabolism and the break down of liver 
metabolized drugs. 2 7 
The lipophilicity of a beta blocker must also be considered. If a 
beta blocker is to be administered topically on the eye it must have 
the right balance of lipophilicity and hydrophilicity. To penetrate the 
cornea, a beta blocker must pass through the epithelium, which is 
lipophilic, then the stroma, which is hydrophilic, and last of all, the 
endothelium which is lipophilic. Lipophilicity is measured by log P, 
log P being the logarithm of the partitioning of a compound in oil to 
its partitioning in water. The corneal permeability of the beta 
blockers plateaus at log P values greater than 2.5. 
The lipophilicity of the beta blockers IS provided by their 
carbon ring component that is partially or completely aromatized. 
Their hydrophilicity originates from their OH group and/or the 
oxygen with the lone pair of electrons that all beta blocker chemical 
structures contain. Therefore, one of the important aspects of 
administering a topically applied beta blocker is that it has the 
proper balance of lipophilicity and hydrophilicity so that it can 
penetrate the cornea and reach the ciliary body through the aqueous 
humor. Lipophilicity must also be considered in hepatic function and 
metabolism. 
Lipid soluble beta blockers are largely metabolized by the 
liver. 18 This has three important implication: the first is the 
possibility of major first-pass metabolism; secondly, if hepatic 
function is impaired, it can cause an accumulation of beta blocker m 
the blood stream; and last of all, the metabolism that occurs can 
sometimes produce active metabolites. First-pass metabolism occurs 
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m the liver mainly with oral administration of a drug. The liver 
breaks down the drug before it has a chance to act which means a 
larger dose of the drug must be given to get a sufficient amount of 
drug through the liver unmetabolized to achieve high enough plasma 
levels to be effective. Active metabolites are merely metabolites 
that can produce a systemic effect. If active metabolites are 
produced, they must be identified so their affects can be considered 
in the overall decision of which beta blocker would be most effective 
and in what amount. If hepatic function is impaired, a decrease in 
liver metabolism will cause the beta blocker to accumulate in the 
blood. Patient's with impaired hepatic function, in general, should 
not be put on lipid soluble beta blockers because the risk of beta 
blocker accumulation leading to overdose is too great. 
Protein binding is another important consideration in 
determining the proper dosage of a beta blocker. Protein binding of 
some beta blockers to certain blood plasma proteins can be 
significant. The degree of binding will affect the amount of drug that 
is available for beta blockage and, once again, the dosage will have to 
be adjusted accordingly. Protein binding, along with first-pass 
metabolism, occurs to differing degrees from person to person and 
thus the bioavailability of a beta blocker can be highly variable. 
Renal function is also important in prescribing a beta blocker. 
The more hydrophilic beta blockers, along with liver 
metabolized active metabolites that are excreted renally, can produce 
an important systemic effect. If a patient has impaired kidney 
function, an accumulation of the beta blocker or active metabolite 
can occur in the blood stream. As a possible overdose of beta 
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blockers could have fatal implications, a patient with renal 
dysfunction must be considered carefully before a beta blocker is 
prescribed. 
Having covered the most important general pharmacological 
effects of the beta blockers, they will now be covered one at a time 
in detail. 
Timolol 
(Timoptic, Blocadren, Timoptol, Chibro-Timoptol) 
Timolol, a non-selective beta blocker, is by far the most used 
beta blocker in the management of glaucoma. It comes in 
concentrations of 0.25%(blue top) and 0.50%(yellow top). In the 
management of glaucoma, Timolol is normally started at 0.25% twice 
a day. If control of the IOP is not achieved the concentration is 
increased to 0.50% twice a day. Since more than 0.50% Timolol twice 
a day has not shown more of a decrease in IOP some different drugs 
must be added to the therapy if control is to be achieved. 
Epinephrine derivatives, miotics, and carbonic anhydras inhibitors 
can be added one at a time to the therapy program until control is 
achieved. In the event that visual field changes are still occurring 
with maximum medications then a filtering bleb or Argon Laser 
Trabeculoplasty(AL T) is indicated. This order of management for 
glaucoma applies to all four of the topical beta blockers. 
Timolol tends to show a slightly larger decrease in IOP than 
Levobunolol or Betaxolol. 23 The mechanism of Timolol in the eye is 
known to be a decrease in aqueous production at the ciliary body. It 
does not have any effect on outflow facility, anterior chamber 
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volume, or endothelial permeability. The decrease in aqueous 
production varies widely from 13% to 48% with a mean and standard 
deviation of 34%±9%.7 Timolol's topical application acts fairly 
quickly with an onset of 1/2 hour, its maximum effect is at about 1-2 
hours, and it has a duration of up to 24 hours. Timolol has a good 
balance of lipophilicity and hydrophilicity with a log P value of 1.91. 
A big advantage that all the topical beta blockers possess is that they 
do not affect the pupils or accommodation like miotics and propine. 
This can be a very valuable factor in dealing with patient compliance 
to the prescribed therapy and proper patient management. 
Timolol is also attractive for systemic use as well. It comes m 
5,10, and 20mg tablets. Normally Timolol is started at lOmg twice a 
day with a maintainence dose between 20-40mg total a day. It 
displays no first-pass metabolism or plasma accumulation in renal 
disease. Some liver metabolism does take place which makes it 
susceptible to accumulation in hepatic dysfunction. One advantage 
though is that little blood plasma protein binding takes place. 
Timolol does not possess any intrinsic sympathomimetic activity and 
therefore should not be abruptly withdrawn. There are two reasons 
for this: The first is that chronic beta blockage can cause some 
patients to develop a hypersensitivity to catecholamines and 
secondly, a beta blocker that has no ISA causes complete beta 
blockage and does not allow the body to maintain very much 
sympathetic tone. In either case, an abrupt withdrawal can cause a 
major influx of sympathetic input which could possibly cause cardiac 
failure in a patient with a weak heart. The systemic mechanism of 
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Timolol is not known but several theories, which will be covered 
under Propranolol, have been hypothesized. 
Timolol is used clinically in managing chronic open angle 
glaucoma, aphakic glaucoma, secondary glaucoma, ocular 
hypertension, and short-term management of angle closure. It also 
finds systemic use in managing hypertension and in reducing the 
risks of mortality in patients that have survived a myocardial infarct. 
Some serious side effects have been documented with the use of 
Timolol. Because of its non-selective beta receptor characteristics, it 
has caused pulmonary distress in patients with chronic obstructive 
pulmonary disease. Care should be used in patients with weak 
hearts because of the decrease in cardiac output and in diabetic 
patients as Timolol can block the signs of acute hypoglycemia. It can 
also mask the signs of hyperthyroidism. When Timolol is used m 
conjunction with catecholamine-depleting drugs, the patient should 
be observed closely for possible additive effects that could occur. 
Timolol is secreted in the milk of nursing mothers and is not 
recommended for them because of the adverse affects a beta blocker 
could have on an infant. Timolol has also been reported to 
occasionally cause systemic side effects such as muscle weakness, 
fatigue, headaches, nausea, dizziness, depression, skin rash, and 
impotence. Ocular side effects include conjunctivitis, blepharitis, 
keratitis, and decreased corneal sensitivity. 
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There are instances when Timolol is contraindicated instead of 
just being used with precaution. These include patients with any 
severe chronic obstructive pulmonary disease or a history thereof, 
sinus bradycardia, second and third degree atrioventricular heart 
block, overt cardiac failure, or cardiogenic shock. 
Betaxolol 
(Betoptic, Kerlone) 
The pharmacology of Betaxolol has several differences from 
Timolol. It comes in 0.50% ophthalmic solution and in a 0.25% 
ophthalmic suspension that has been shown to be significantly more 
comfortable than the solution.2 It is normally administered one drop 
twice a day for the solution or the suspension. For systemic use it 
comes in 10 and 20mg tablets, is usually started at 10mg once a day, 
and is normally not administered more than 20mg once a day. It is 
beta1 selective in nature which is a distinct advantage in that it has 
shown very little effect in decreasing lung capacity or in lowering 
blood pressure when topically applied. 2 Since it is only approved for 
the management of glaucoma, its main administration is topically. 
Betaxolol has also shown an additive effect when used in conjunction 
with epinephrine.17 An additional decrease in lOP was achieved 
when epinephrine was added to Betaxolol therapy; This additional 
decrease was attributed to an increase in outflow facility caused by 
the epinephrine. With a log P value of 2.73, Betaxolol is very 
lipophilic but still manages to penetrate the cornea sufficiently to be 
effective when topically applied. Being lipophilic also makes it prone 
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to causmg corneal anesthesia by stabilizing the membranes of the 
unmylenated nerves in the cornea but this has been reported only 
rarely. The mechanism of Betaxolol has been shown to be a decrease 
in aqueous humor production with no effect on outflow facility .g It 
decreased aqueous humor production between 7% and 51% with a 
mean and standard deviation of 32%±13%. It has an onset of l/2 
hour, a maximum effect at about 2 hours, and lasts only around 12 
hours. Betaxolol's duration is only about half of Timolol's. This may 
be due to Betaxolol's much higher lipophilicity which makes it more 
prone to liver metabolism. 
Clinically, Betaxolol is limited m use because it is only FDA 
approved for topical administration. Therefore, it is only used in 
managing glaucoma and ocular hypertension. 
Ocular side effects to watch for include keratitis, decreased 
corneal sensitivity, and photophobia. Systemic side effects that have 
been reported in rare instances include dyspnea, bradycardia, 
impotence, headache, insomnia, and depression. Caution should be 
used in patients taking catecholamine-depleting drugs because of 
possible additive effects and in nursing mother and children. 
Betaxolol is contraindicated when the patient has sinus 
bradycardia, greater than first degree atrioventricular heart block, 
cardiogenic shock, overt cardiac failure, or severe chronic obstructive 
pulmonary disease. 
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Levobunolol 
(Betagan, Bunorit, Gotensin, Vistagan) 
Levobunolol is another beta blocker that has only been FDA 
approved for ocular use in the US. It comes in ophthalmic solutions 
of 0.25% and 0.50%. The 0.50% solution is normally started out once 
a day while the 0.25% solution is started out twice a day. The 0.50% 
can be used twice a day but more frequent administration than this 
is generally not effective. Levobunolol shows no beta receptor 
selectivity, is between Timolol and Betaxolol in lipophilicity with a 
log P value of 2.4 and possesses no intrinsic sympathomimetic 
activity. As with other beta blockers, Levobunolol decreases 
aqueous humor production at the ciliary body but does not increase 
outflow facility at the trabecular meshwork.19 It has also displayed 
the longest time to onset at about 1 hour with a maximum effect 
between 2-6 hours. A significant decrease in lOP can be maintained 
for up to 24 hours. This can be a big advantage in certain cases 
where patient compliance is a problem since Levobunolol can 
actually be used once a day with relatively good results in some 
patients. 
Levobunolol, like Timolol, has been shown to cause significant 
systemic beta blockage in the heart and lungs. An average 4-5 beat 
per minute decrease in heart rate was observed.g Occasional reports 
of pulmonary distress and corneal anesthesia have also occurred. 
Other systemic side effects that have been observed include , 
headache, impotence, dizziness, heart block, congestive heart failure, 
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nausea, depression, and skin rash. Ocular side effects that have been 
observed are a burning sensation upon corneal application and 
hyperemia of the eyelids and conjunctivia. Caution should be 
exercised in nursing mothers, in children, and m patients who are 
taking catecholamine-depleting drugs because of possible additive 
effects. 
The clinical uses of Levobunolol are very limited as it is only 
FDA approved for ocular use. Accordingly, it is only used in the 
management of glaucoma and ocular hypertension to lower lOP. 
Situations where Levobunolol is contraindicated include 
patients with any severe chronic obstructive pulmonary disease, 
sinus bradycardia, second and third degree atrioventricular heart 
block, cardiogenic shock, and overt cardiac failure. 
METIPRANOLOL 
(OPTlPRANOLOL) 
Metipranolol is the most recent addition to the topical beta 
blockers that are approved for glaucoma therapy in the U.S.. It is a 
non-selective beta blocker that has been shown to be as effective as 
Timolol in lowering lOP of the eye. It works by decreasing aqueous 
production at the ciliary body, but in addition may also slightly 
increase outflow facility. Metipranolol does tend to burn more upon 
topical application than the other three beta blockers but not enough 
to warrant discontinuing its use in most cases. Its onset of action for 
topical administration is one half hour, with a maximum effect at two 
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hours, and a duration of 24 hours. The mechanism of Metipranolol is 
not known but is felt to be similar to the three main theories of beta 
blocker action covered under Propanolol. 
Clinically, Metipranolol is used for managing primary open-
angle glaucoma, the secondary glaucomas, ocular hypertension and 
short-term management of angle closure. It comes in a concentration 
of 0.3% and is normally administered twice a day with good results. 
Caution must be used in patients with cerebrovascular insufficiency, 
chronic obstructive pulmonary disease, in patients receiving any 
catecholamine-depleting drugs, and in nursing mothers and children. 
It can also cause problems in diabetes and hyperthyroidism by 
masking some of the signs and symptoms of these two diseases. 
Ocular side effects include conjunctivitis, blepharitis, tearing, blurred 
vision, and photophobia. In addition, Metipranolol has been 
reported, in rare cases, to cause headaches, bradycardia, dyspnea, 
dizziness, anxiety, depression, impotence,and nausea. 
Patients in which Metipranolol is contraindicated include those 
with COPD, symptomatic sinus bradycardia, second or third degree 
atrioventricular heart block, cardiogenic shock, and overt cardiac 
failure. 
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Propranolol 
(lnderal, Dociton) 
Propranolol is the most popular beta blocker for treating 
systemic hypertension, angina, and arrhythmia. It comes in several 
different forms including 10,20,40,60,80mg tablets, in lmg/ml 
intravenous solution, and in 60,80, 120, 160mg Long Acting tablets 
that last up to 24 hours. A normal starting dose is 40mg(regular 
tablets) twice a day with a maintanence dose of 120-240mg total per 
day. It also comes m various combinations with hydrochlorothiazide 
called Inderide. It has displayed no beta receptor selectivity or 
intrinsic sympathomimetic activity. Propranolol is very lipophilic 
with a log P value of 3.2 which means it will be largely metabolized 
by the liver and in fact, does show a large first-pass metabolism. 
This leads to a larger dose requirement to obtain sufficient blood 
plasma concentrations so beta blockade can be achieved. It must be 
used with caution in patients with hepatic dysfunction because 
slower liver metabolism of Propranolol can greatly increase its blood 
plasma levels. There have been three theories proposed as to the 
mechanism by which Propranolol works: these are a decrease in 
cardiac output, an inhibition of renin release by the kidneys, or a 
decrease of the tonic sympathetic nerve outflow from the vasomotor 
centers in the brain.2 The mechanism could be one or a combination 
of any of these theories. Propranolol's maximum effect occurs 
around 1-1/2 to 2 hours and because of extensive liver metabolism 
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only lasts about 12 hours. The long acting type of Propranolol lasts 
up to 24 hours. 
There are a wide range of clinical uses for Propranolol. As 
mentioned earlier, its main areas of use are in managing 
hypertension, angina, and arrhythmias of the heart. It is also used in 
patients who have stabilized after a myocardial infarct to lessen the 
risk of another, in managing hypertrophic subaortic stenosis, and 
occasionally in preventative treatment of migraine headaches. 
Propranolol has some potentially serious sides effects. Due to 
its high lipophilicity, it is better able to penetrate the brain tissues 
and cause psychological problems such as mental depression, 
lassitude, hallucinations, short-term memory loss, and disorientation. 
It has been shown to cause a decrease in pulmonary capacity like 
most of the other beta blockers. There are also reported cases of 
insomnia, muscle weakness, fatigue, visual disturbances, dry eyes, 
nausea, abdominal cramps, skin rash from allergic reactions, 
agranulocytosis, male impotence, and drug induced deafness. One of 
the big advantages of Propranolol is that it reduces high density 
lipoproteins and therefore, the cholesterol ratio. This helps in 
preventing plaque build-up in the blood vessels and thus helps 
decrease the risk of myocardial infarct. Propranolol, in general, 
reduces the oxygen requirements of the heart at any given level of 
effort. This is an advantage in treating angina. Propranolol also 
causes a significant decrease in lOP of the eye. 
Contraindications for Propranolol are cardiogenic shock, sinus 
bradycardia, second or third degree atrioventricular heart block, and 
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severe chronic obstructive pulmonary disease or any history thereof, 
and congestive heart failure. 
Acebutolol 
(Sectral) 
Acebutolol's pharmocology is fairly colorful. It comes in 200 
and 400mg tablets. Normally 400mg once a day is the initial dose 
with a maintanence dose of 400-800mg total per day. In some 
patients twice a day dosing may be required to control blood 
pressure. It possesses both beta1 receptor selectivity and intrinsic 
sympathomimetic activity. The betat selectivity produces less 
problems in decreased pulmonary capacity and the ISA allows for 
some sympathetic tone to be maintained which can be important in 
patients with weak hearts. It displays only moderate lipophilicity 
but enough that liver metabolism does occur and the active 
metabolites that are produced in this instance must be considered 
when prescribing it. On the other hand, it is hydrophilic enough that 
it, along with the active metabolites, are eliminated mainly through 
the renal system. In patients with kidney dysfunction, Acebutolol 
can accumulate in the blood plasma leading to a possible overdose. 
Protein binding in the blood plasma occurs significantly enough to 
also be considered. In geriatric patients, a larger proportion of the 
dosage reaches the blood plasma probably because of less hepatic 
metabolism and renal ability. The mechanism of Acebutolol is not 
known for sure but it is felt to be similar to that of Propranolol's. 
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Maximum effect of Acebutolol is realized m about 2-1/2 to 3 hours 
and can last for up to 24 hours. 
Clinically, Acebutolol is somewhat limited in use, finding its 
main administration in two cases: treatment of premature 
ventricular beats and in systemic hypertension. 
Some of the side effects that have been observed m the use of 
Acebutolol include bradycardia, hypotension, heart failure, decreased 
pulmonary capacity, nausea, anxiety, conjunctivitis, and dry eyes. 
One disadvantage of Acebutolol is that its liver metabolism produces 
an active metabolite. This causes large differences in blood plasma 
concentrations from patient to patient because of differing degrees of 
hepatic function. Boundaries to be crossed with caution are patients 
with hepatic or renal dysfunction and in pregnant or nursing 
females. An additive effect should be watched for in patients 
receiving catecholamine-depleting drugs. Signs of thyrotoxicosis can 
be masked by Acebutolol' s use. It has also been shown that a 
decrease of lOP in the eye occurs. 
In patients with bradycardia, second or third degree 
atrioventricular heart block, cardiogenic shock, or overt cardiac 
failure, the use of Acebutolol is contraindicated. 
Metoprolol 
(Lopressor, Beloc) 
Metoprolol is another of the beta blockers that exhibits 
extensive beta1 selectivity which, as with the other beta1 selective 
beta blockers, lends itself to use m patients with chronic obstructive 
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pulmonary disease. It comes in 100 and 200mg tablets, in 5ml 
ampuls for intravenous administration, and in combination with 
hydrochlorothiazide called Lopressor HCT. It is usually started at a 
dose of 1 OOmg total once or twice a day with a usual maintanence 
dose of between 1 00-450mg. It possesses no intrinsic 
sympathomimetic activity. With a log P value of 1.88, Metoprolol has 
about the same lipophilicity as Timolol. This characteristic makes the 
probability of liver metabolism more likely and, in fact, it proves to 
be a significant factor in the administration of Metoprolol. It 
displays only a small amount of first-pass metabolism though, and 
produces no active metabolites from the liver metabolism that does 
take place. Elimination occurs mainly through the liver. Metoprolol 
has shown minimal protein binding, it does not tend to accumulate m 
patients with renal dysfunction, and favorably affects blood lipid 
levels. The mechanism of Metoprolol, like all the other beta blockers, 
has not been determined for sure but one or a combination of the 
following are felt to be involved: decreased cardiac output by 
adrenergic beta blockage at the heart, reduced renin release by the 
kidneys, or a decrease in sympathetic outflow from the brain to the 
periphery. Onset of Metoprolol beta blockade occurs within an hour 
with maximum effect at 4-6 hours and a single dose lasting up to 24 
hours. It is also FDA approved for intravenous administration for a 
quicker onset with maximum effect at about 20 minutes. 
The use of Metoprolol is indicated in patients with angma, 
hypertension, and in reducing the risk of death after an acute heart 
attack. It is the only beta blocker approved for use during a heart 
attack. 
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Some of the advantages of Metoprolol are its beta1 selectivity, 
its lack of active metabolites, and it reduces oxygen requirements of 
the heart. A major disadvantage is its significant penetration into 
the central nervous system which leads to many of the negative side 
effects of its use. Side effects that have been observed are dizziness, 
headaches, nightmares, insomnia, mental confusion, short-term 
memory loss, nausea, fatigue, cold extremities, and dry eyes. It has 
also been shown to lower lOP in the eye. 
Contraindications for Metoprolol are as follows: sinus 
bradycardia, heart block greater than first degree, overt cardiac 
failure, and cardiogenic shock. 
Pindolol 
(Visken, Durapindol) 
Pindolol is an adrenergic beta blocker that displays no beta 
receptor selectivity but does exhibit considerable intrinsic 
sympathomimetic activity. The ISA of Pindolol allows it to maintain 
some sympathetic tone which is important in patients with a history 
of cardiac failure. Beta blockers with ISA also tend to cause less of a 
disturbance in some metabolic processes such as lipid metabolism.2 7 
It comes in 5 and lOmg tablets, with an initial dose of 5mg twice a 
day, and a maintanence dose of 1 0-60mg total per day. The 
mechanism of Pindolol has not been discovered. A reduced 
sympathetic outflow from the brain, a decrease in renin release, and 
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a decrease in cardiac output are the main-line theories of beta 
blocker action but they seem less likely in Pindolol's case because of 
its modest affect on cardiac output and renin release. It has been 
shown to be as effective as Propranolol in reducing both systolic and 
diastolic blood pressure.2 Pindolol does not exhibit any first-pass 
metabolism, produces no active metabolites, and shows no 
accumulation in kidney disease. An accumulation in the blood 
plasma does occur in patients with decreased hepatic function 
though. Pindolol does possess considerable protein binding ability 
that must be considered when prescribing it. Pindolol has an onset 
of about 1 hour, a maximum effect at 2-3 hours, and lasts only about 
12 hours with a single dose. 
Clinically, Pindolol is used only for the management of 
hypertension. It works well though because its ISA maintains a 
degree of sympathetic tone while also causing a vasodilation which 
decreases peripheral resistance. This is the opposite of nearly all 
other beta blockers which normally cause an increase in peripheral 
resistance. It does have the disadvantage of causing some edema 
though. 
Pindolol has various side effects that are common to most beta 
blockers. These include pulmonary distress, heart block, diarrhea, 
nausea, male impotence, and burning eyes. Precautions must be 
exercised in diabetic patients as it can mask the signs of 
hypoglycemia, in patients with decreased hepatic function because of 
possible plasma accumulation, and in patients with a history of 
cardiac failure. Pindolol should not be abruptly withdrawn after 
chronic use as a hypersensitivity to catecholamines has developed m 
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some patients. Thus, abrupt withdrawal can lead to excessive 
sympathetic input and consequent heart failure. Pindolol has 
exhibited an ocular effect by reducing lOP. 
In patient who show signs of severe bradycardia, chronic 
obstructive pulmonary disease, cardiogenic shock, second or third 
degree atrioventricular heart block, or overt cardiac failure Pindolol 
is contraindicated. 
Nadolol 
(Corgard) 
N adolol is a beta blocker that is similar to Timolol. It comes m 
20,40,80, 120, 160mg tablets. An initial dose is usually 40mg once a 
day with a maintanence dose of 40-80mg total per day. It displays 
very weak lipophilicity with a log P value of only .93. This means 
elimination through the renal system is predominate. Accumulation 
of Nadolol in the blood plasma must therefore be watch for closely in 
patients with any decreased kidney function. N adolol does maintain 
renal blood flow and the glomerular filtration rate though, unlike 
most other beta blockers.11 It has shown no evidence of any beta 
receptor selectivity or intrinsic sympathomimetic activity. Liver 
metabolism does occur to a sufficient degree that it must be 
considered in prescribing Nadolol but no active metabolites of 
consequence are produced. There is no major first-pass metabolism 
that occurs and, in fact, Nadolol is only one of two beta blockers that 
are excreted by the kidneys unchanged. 11 Protein binding occurs to 
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a considerable extent and can affect availability of N adolol. The 
mechanism of N adolol has not been determined but is thought to be 
similar to the other beta blocker mechanism theories. Onset of action 
is about 1 hour, with peak effect at 3-4 hours, and a duration of up 
to 24 hours. 
N adolol finds two mam areas of use. The first being the 
management of angina as Nadolol tends to reduce oxygen 
requirements of the heart. Management of hypertension is its 
second clinical application. Nadolol does not have a direct depressant 
effect on the heart like most of the other beta blockers which is an 
advantage in treating hypertension. 
Side effects of N adolol, like the other beta blockers, are 
numerous but uncommon. They include dizziness, fatigue, 
depression, hallucinations, disorientation, visual disturbances, short-
term memory loss, insomnia, bradycardia, hypotension, weight gain, 
skin rash, headaches, and respiratory distress. Nadolol should be 
used cautiously in pregnant and nursing females. 
Contraindications of Nadolol include the following: bronchial 
asthma, sinus bradycardia, second or third degree atrioventricular 
heart block, cardiogenic shock, and overt cardiac failure. 
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Labetalol 
(N ormodyne, Trandate) 
Labetalol is a unique, non-selective beta blocker in that it also 
selectively blocks alpha receptors. The ratio of alpha to beta 
blockade has been estimated to be about 1 :3 for oral administration 
and 1 :7 for intravenous administration.z The additional alpha 
blockade results in less peripheral resistance and, unlike most of the 
other beta blockers, cardiac output is not decreased.zg It comes in 
100,200,300mg tablets and in Smg/ml intravenous solution. An 
initial dose of 100mg twice a day is recommended with a 
maintanence dose of 200-400mg twice a day. Labetalol is 
metabolized by the liver and exhibits major first-pass metabolism 
but does not produce any active metabolites of concern. Being 
eliminated by the liver, Labetalol does not show any accumulation in 
renal disease but hepatic disease can cause a decreased breakdown 
of it and thus an accumulation. It has also exhibited considerable 
protein binding ability that must be taken into account. Labetalol 
has displayed some intrinsic sympathominetic activity by causing 
slight beta agonistic activity but it is minimal. This could be a 
possible explanation of why Labetalol does not cause a decrease m 
heart rate. Onset of action depends on the type of administration. 
For intravenous administration, onset is nearly immediate with 
maximum effect within 5 minutes and a duration of about 12 hours. 
When administered orally, onset is within an hour, 2-4 hours for 
peak effect, and a duration of about 12 hours. 
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In the clinical setting, Labetalol is used m managing 
hypertension and hypertensive emergencies. The immediate action 
of Labetalol in IV, along with the advantage of no decrease in cardiac 
output, is important in managing hypertensive emergencies when 
the condition of the patient's heart is not known. Other advantages 
of Labetalol are its vasodilatory effect that decreases peripheral 
resistance, a lack of effect on kidney function, and less pulmonary 
problems. Disadvantages include its large first-pass metabolism and 
extensive protein binding that causes major variations in the amount 
of Labetalol that is actually available for blockade from patient to 
patient. It has not shown a positive effect on blood lipid levels like 
nearly all the other beta blocker. This is a major disadvantage when 
managing patients with hypertension and atherosclerosis. 
Labetalol has shown side effects similar to the other beta 
blockers such as fatigue, nausea, edema, depression, bradycardia, 
pulmonary distress, skin rash, and visual disturbances, In addition, 
there have been reports of muscle cramps, jaundice, and difficulty in 
urinating. A decrease of lOP in the eye has also be documented. 
Contraindications for Labetalol include chronic obstructive 
pulmonary disease, bradycardia, overt cardiac failure, cardiogenic 
shock, and second or third degree atrioventricular heart block. 
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Atenolol 
(Tenermin) 
Atenolol is a beta blocker that has several interesting 
pharmacological aspects. It is supplied in 50 and IOOmg tablets, m a 
l/2 mg/ml intravenous solution, and in tablet form in combination 
with chlorthalidone called Tenoretic. It is usually started at a dose of 
50mg once a day with a maintanence dose of 50-IOOmg once a day. 
It has the least lipophilicity of any of the beta blockers with a log P 
value of only .16. This causes the drug to show very little central 
nervous system penetration which is useful in treating patients with 
mental disorders and in lessening many of the potentially harmful 
side effects of beta blockers caused by CNS penetration. Being more 
hydrophilic also means less liver metabolism which alleviates any 
major first-pass metabolism. Along with very low protein binding m 
the plasma, this helps Atenolol achieve a less variable bioavailability 
from patient to patient. Atenolol also exhibits high beta1 receptor 
selectivity which lends itself to less peripheral vascular resistance 
along with less of a reduction in pulmonary capacity. As with other 
renally excreted drugs, an accumulation of Atenolol can occur in 
patients with impaired kidney function. The onset of Atenolol takes 
about 1 hour, with peak effect from 2-4 hours, and a duration of up 
to 24 hours. 
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Clinically, Atenolol is used in the management of hypertension. 
Its beta selectivity is helpful in decreasing peripheral vascular 
resistance and pulmonary problems that may occur from 
administration. It is also a good pick for treating angina as it 
normally reduces the amount of oxygen needed by the heart. 
Most of the side effects of Atenolol are quite rare. Some of the 
more serious ones include cardiac failure, pulmonary distress, 
agranulocytosis, and mental depression progressing to catatonia. 
Other less serious ones are fatigue, nausea, leg pain, bradycardia, and 
cold extremities. A reduction of lOP in the eye has been observed. 
Atenolol 1s contraindicated in sinus bradycardia, cardiogenic 
shock, second or third degree atrioventricular heart block, and overt 
cardiac failure. Precautions should be exercised in patients with 
reduced renal function and steps must be taken to monitor possible 
additive effects if any catecholamine-depleting drugs are being taken 
in conjunction with Atenolol. In addition, Atenolol therapy should 
not be abruptly withdrawn as it can lead to cardiac failure caused by 
hypersensitivity to catecholamines that may have developed during 
extended beta blockade. 
Beta blocker drugs, although all fairly similar, have subtly, yet 
important differences. Their lipophilicity, liver metabolism, active 
metabolites, beta receptor selectivity, and protein binding ability are 
some of the most important characteristics that must be considered 
in administration. Each patient has different health characteristics 
that must be considered to find the most effective beta blocker to 
achieve the safest possible beta blockage. In practice all beta 
blockers are not the same. 
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Recently several other beta blockers have met Federal 
approval for systemic use. These are Esmolol, an ultra-short acting 
beta blocker, and Oxprenolol. Some of the beta blockers, other than 
Timolol, Betaxolol, Levobunolol, and Metipranolol have also met 
foreign governments' approval for ocular use. These include 
Befunolol, Bupranolol, Carteolol, and Pindolol. 
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APPENDIX 1 
Beta1 ISA Lipid First-pass Active Protein 
Selectivity Soluability Metabolism Metabolites Binding 
Acebutolol X X Moderate X 
Atenolol X logP=0.16 
Betaxolol X logP=2.73 
Labetalol X Weak X X 
Levobunolol logP=2.4 
Metipranolol Moderate 
Metoprolol X logP=1.88 
Nadolol logP=0.93 X 
Pindolol X Moderate X 
Propranolol logP=3.21 X X X 
Timolol logP=1.91 
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